natgillin/translations-raw huggingface dataset:
Commission Regulation (EC) No 1455/2004 of 16 August 2004 concerning the authorisation for 10 years of the additive ‘Avatec 15 %’ in feedingstuffs, belonging to the group of coccidiostats and other medicinal substances ( OJ L 269, 17.8.2004, p. 14).
Uredba Komisije (ES) št. 1455/2004 z dne 16. avgusta 2004 o desetletni odobritvi dodatka „Avatec 15 %“ v krmnih mešanicah, ki spada v skupino kokcidiostatikov in drugih zdravilnih snovi ( UL L 269, 17.8.2004, str. 14).
Commission Regulation (EC) No 1800/2004 of 15 October 2004 concerning the authorisation for 10 years of the additive Cycostat 66G in feedingstuffs, belonging to the group of coccidiostats and other medicinal substances (OJ L 317, 16.10.2004, p. 37).
Uredba Komisije (ES) št. 1800/2004 z dne 15. oktobra 2004 o odobritvi dodatka v krmi „Cycostat 66G“ iz skupine kokcidiostatikov in drugih zdravilnih učinkovin za obdobje desetih let ( UL L 317, 16.10.2004, str. 37).
Commission Regulation (EC) No 600/2005 of 18 April 2005 concerning a new authorisation for 10 years of a coccidiostat as an additive in feedingstuffs, the provisional authorisation of an additive and the permanent authorisation of certain additives in feedingstuffs (OJ L 99, 19.4.2005, p. 5).
Uredba Komisije (ES) št. 600/2005 z dne 18. aprila 2005 o izdaji novega dovoljenja za kokcidiostatik kot dodatek v krmi za deset let, začasnega dovoljenja za dodatek in trajnega dovoljenja za nekatere dodatke v krmi (UL L 99, 19.4.2005, str. 5).
Commission Regulation (EU) No 874/2010 of 5 October 2010 concerning the authorisation of lasalocid A sodium as a feed additive for turkeys up to 16 weeks (holder of authorisation Alpharma (Belgium) BVBA) and amending Regulation (EC) No 2430/1999 (OJ L 263, 6.10.2010, p. 1).
Uredba Komisije (EU) št. 874/2010 z dne 5. oktobra 2010 o izdaji dovoljenja za lasalocid A natrij kot krmni dodatek za purane do 16 tednov (imetnik dovoljenja Alpharma (Belgija) BVBA) ter o spremembi Uredbe (ES) št. 2430/1999 (UL L 263, 6.10.2010, str. 1).
Commission Implementing Regulation (EU) No 388/2011 of 19 April 2011 concerning the authorisation of maduramicin ammonium alpha as a feed additive for chickens for fattening (holder of authorisation Alpharma (Belgium) BVBA) and amending Regulation (EC) No 2430/1999 (OJ L 104, 20.4.2011, p. 3).
Izvedbena uredba Komisije (EU) št. 388/2011 z dne 19. aprila 2011 o izdaji dovoljenja za alfa amonijev maduramicin kot krmni dodatek za piščance za pitanje (imetnik dovoljenja je Alpharma (Belgija) BVBA) ter o spremembi Uredbe (ES) št. 2430/1999 (UL L 104, 20.4.2011, str. 3).
Commission Implementing Regulation (EU) No 532/2011 of 31 May 2011 concerning the authorisation of robenidine hydrochloride as a feed additive for rabbits for breeding and rabbits for fattening (holder of authorisation Alpharma Belgium BVBA) and amending Regulations (EC) No 2430/1999 and (EC) No 1800/2004 (OJ L 146, 1.6.2011, p. 7).
Izvedbena uredba Komisije (EU) št. 532/2011 z dne 31. maja 2011 o izdaji dovoljenja za robenidin hidroklorid kot krmni dodatek za plemenske kunce in kunce za pitanje (imetnik dovoljenja je Alpharma (Belgija) BVBA) ter o spremembi uredb (ES) št. 2430/1999 in (ES) št. 1800/2004 (UL L 146, 1.6.2011, str. 7).
Commission Implementing Regulation (EU) No 900/2011 of 7 September 2011 concerning the authorisation of lasalocid A sodium as a feed additive for pheasants, guinea fowl, quails and partridges other than laying birds (holder of authorisation Alpharma (Belgium) BVBA) (OJ L 231, 8.9.2011, p. 15).
Izvedbena uredba Komisije (EU) št. 900/2011 z dne 7. septembra 2011 o izdaji dovoljenja za lasalocid A natrij kot krmni dodatek za fazane, pegatke, prepelice in jerebice, razen nesnic (imetnik dovoljenja je družba Alpharma (Belgija) BVBA) (UL L 231, 8.9.2011, str. 15).
Commission Implementing Regulation (EU) No 1015/2013
Izvedbena uredba Komisije (EU) št. 1015/2013
Commission Implementing Regulation (EU) No 1016/2013
Izvedbena uredba Komisije (EU) št. 1016/2013
concerning the authorisation of a preparation of a micro-organism strain DSM 11798 of the Coriobacteriaceae family as a feed additive for pigs
o izdaji dovoljenja za pripravek mikroorganizma iz seva DSM 11798 družine Coriobacteriaceae kot krmni dodatek za prašiče
In accordance with Article 7 of Regulation (EC) No 1831/2003, an application was submitted for the authorisation of a preparation of a micro-organism strain DSM 11798 of the Coriobacteriaceae family.
V skladu s členom 7 Uredbe (ES) št. 1831/2003 je bil vložen zahtevek za izdajo dovoljenja za pripravek mikroorganizma iz seva DSM 11798 družine Coriobacteriaceae.
That application concerns the authorisation of a preparation of a micro-organism strain DSM 11798 of the Coriobacteriaceae family as a feed additive for pigs, to be classified in the additive category ‘technological additives’.
Navedeni zahtevek zadeva dovoljenje za pripravek mikroorganizma iz seva DSM 11798 družine Coriobacteriaceae kot krmni dodatek za prašiče in njegovo uvrstitev v kategorijo dodatkov „tehnološki dodatki“.
The European Food Safety Authority (‘the Authority’) in its opinion of 16 April 2013 [2] concluded that, under the proposed conditions of use, the preparation of a micro-organism strain DSM 11798 of the Coriobacteriaceae family is safe for the target species, for the human health and for the environment.
Evropska agencija za varnost hrane (v nadaljnjem besedilu: Agencija) je v mnenju z dne 16. aprila 2013 [2] navedla, da je uporaba pripravka mikroorganizma iz seva DSM 11798 družine Coriobacteriaceae pod predlaganimi pogoji uporabe varna za ciljne vrste, za zdravje ljudi in za okolje.
It recognised that it has the capacity to biotransform trichothecenes from contaminated feed for pigs.
Potrdila je, da lahko biotransformira trihotecene v onesnaženi krmi za prašiče.
The assessment of the preparation of a micro-organism strain DSM 11798 of the Coriobacteriaceae family shows that the conditions for authorisation, as provided for in Article 5 of Regulation (EC) No 1831/2003, are satisfied.
Ocena pripravka mikroorganizma iz seva DSM 11798 družine Coriobacteriaceae je pokazala, da so pogoji za dovoljenje iz člena 5 Uredbe (ES) št. 1831/2003 izpolnjeni.
The preparation specified in the Annex, belonging to the additive category ‘technological additives’ and to the functional group ‘substances for the reduction of the contamination of feed by mycotoxins’, is authorised as an additive in animal nutrition subject to the conditions laid down in that Annex.
Pripravek iz Priloge, ki spada v kategorijo dodatkov „tehnološki dodatki“ in funkcionalno skupino „snovi za zmanjševanje kontaminacije krme z mikotoksini“, se dovoli kot dodatek v prehrani živali v skladu s pogoji iz navedene priloge.
EFSA Journal 2013; 11(5):3203.
EFSA Journal 2013; 11(5): 3203.
Functional group: substances for the reduction of the contamination of feed by mycotoxins: Deoxynivalenol (DON)
Funkcionalna skupina: snovi za zmanjševanje kontaminacije krme z mikotoksini: deoksinivalenol (DON)
Micro-organism strain DSM 11798 of the Coriobacteriaceae family
mikroorganizem iz seva DSM 11798 družine Coriobacteriaceae
Preparation of a micro-organism strain DSM 11798 of the Coriobacteriaceae family containing a minimum of 5 × 109 CFU/g of additive.
pripravek mikroorganizma iz seva DSM 11798 družine Coriobacteriaceae z najmanjšo vsebnostjo dodatka 5 × 109 CFU/g
Viable cells of: micro-organism strain DSM 11798 of the Coriobacteriaceae family
žive celice mikroorganizma iz seva DSM 11798 družine Coriobacteriaceae
Analytical method [1]Enumeration of micro-organism strain DSM 11798 of the Coriobacteriaceae family: pour plate method using VM agar supplemented with Oxyrase.
Analitske metode [1]Štetje mikroorganizmov iz seva DSM 11798 družine Coriobacteriaceae: metoda razlitja na plošči z uporabo agarja VM z dodatkom Oxyrase.
Identification of micro-organism strain DSM 11798 of the Coriobacteriaceae family: Pulsed Field Gel Electrophoresis (PFGE).
Identifikacija mikroorganizma iz seva DSM 11798 družine Coriobacteriaceae: gelska elektroforeza v pulzirajočem polju (PFGE).
The use of the additive is allowed in feedingstuffs complying with the European Union legislation on undesirable substances in animal feed.
Uporaba dodatka je dovoljena v krmi, ki je v skladu z zakonodajo Evropske unije o neželenih snoveh v živalski krmi.
For safety: it is recommended to use breathing protection and gloves during handling.
Zaradi varnosti se pri ravnanju se priporoča uporaba zaščite za dihala in rokavic.
Details of the analytical methods are available at the following address of the Reference Laboratory: http://www.jrc.ec.europa.eu/EURLs/EURL_feed_additives/Pages/index.aspx
Podrobnosti o analitskih metodah so na voljo na naslovu referenčnega laboratorija: http://irmm.jrc.ec.europa.eu/EURLs/EURL_feed_additives/Pages/index.aspx
Commission Regulation (EU) No 1017/2013
Uredba Komisije (EU) št. 1017/2013
Following an application from Ceprodi KOT, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of ‘hypo-caloric snacks (KOT products)’ on reduction of adipocyte size at the abdominal level in the context of a low-calorie diet (Question No EFSA-Q-2011-00016) [2].
Družba Ceprodi KOT je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki „hipokaloričnih prigrizkov (izdelkov KOT)“ na zmanjšanje velikosti maščobnih celic na trebuhu pri nizkokalorični prehrani (vprašanje št. EFSA-Q-2011-00016) [2].
The claim proposed by the applicant was worded as follows: ‘Contributes to reduce the adipocytes size at the abdominal level, in the context of a low-calorie diet’.
Vlagatelj je predlagal naslednjo trditev: „Prispevajo k zmanjšanju velikosti maščobnih celic na trebuhu pri nizkokalorični prehrani.“
On 30 September 2011, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of ‘hypo-caloric snacks (KOT products)’ and a beneficial physiological effect related to the reduction of subcutaneous adipocyte size at the abdominal level.
Komisija in države članice so 30. septembra 2011 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem „hipokaloričnih prigrizkov (izdelkov KOT)“ in pozitivnim fiziološkim učinkom, povezanim z zmanjšanjem velikosti podkožnih maščobnih celic na trebuhu, ni utemeljena.
Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.
Ker zdravstvena trditev ne izpolnjuje zahtev iz Uredbe (ES) št. 1924/2006, se ne bi smela odobriti.
Following an application from Valio Ltd, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of isoleucyl-prolyl-proline (IPP) and valyl-prolyl-proline (VPP) on maintenance of normal blood pressure (Question No EFSA-Q-2011-00121) [3].
Družba Valio Ltd je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki izolevcil-prolil-prolina in valil-prolil-prolina na vzdrževanje normalnega krvnega tlaka (vprašanje št. EFSA-Q-2011-00121) [3].
The claim proposed by the applicant was worded as follows: ‘Peptides IPP and VPP help to maintain normal blood pressure’.
Vlagatelj je predlagal naslednjo trditev: „Peptida izolevcil-prolil-prolin in valil-prolil-prolin pomagata vzdrževati normalni krvni tlak.“
On 30 September 2011, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of IPP and VPP and the claimed effect.
Komisija in države članice so 30. septembra 2011 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem izolevcil-prolil-prolina in valil-prolil-prolina ter navedeno trditvijo ni utemeljena.
Following an application from Diana Naturals, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Appl’In® polyphenolic apple extract powder (Malus domestica) on reduction of post-prandial glycaemic responses (Question No EFSA-Q-2011-00190) [4].
Družba Diana Naturals je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki polifenolnega izvlečka iz jabolk (Malus domestica) v prahu Appl’In® na zmanjšanje glikemičnih odzivov po obroku (vprašanje št. EFSA-Q-2011-00190) [4].
The claim proposed by the applicant was worded as follows: ‘Appl’In® contributes to decrease glycaemic response in women’.
Vlagatelj je predlagal naslednjo trditev: „Appl’In® prispeva k zmanjšanju glikemičnih odzivov pri ženskah.“
On 5 October 2011, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of Appl’In® and the claimed effect.
Komisija in države članice so 5. oktobra 2011 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem Appl’In® in navedeno trditvijo ni utemeljena.
Following an application from Tchibo GmbH, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the consumption of coffee C21 and reduction of spontaneous DNA strand breaks (Question No EFSA-Q-2011-00783) [5].
Družba Tchibo GmbH je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z uživanjem kave C21 in zmanjšanjem spontanega trganja verige DNK (vprašanje št. EFSA-Q-2011-00783) [5].
The claim proposed by the applicant was worded as follows: ‘Regular consumption of Coffee C21 contributes to the maintenance of DNA integrity in cells of the body’.
Vlagatelj je predlagal naslednjo trditev: „Redno uživanje kave C21 prispeva k ohranjanju celovitosti DNK v telesnih celicah.“
On 5 December 2011, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of coffee C21 and the claimed effect.
Komisija in države članice so 5. decembra 2011 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem kave C21 in navedeno trditvijo ni utemeljena.
Following an application from Kao Corporation, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of diacylglycerol (DAG) oil and reduction of body weight (Question No EFSA-Q-2011-00751) [6].
Družba Kao Corporation je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki diacilglicerolnega olja na zmanjšanje telesne teže (vprašanje št. EFSA-Q-2011-00751) [6].
The claim proposed by the applicant was worded as follows: ‘Substituting your usual vegetable oil with DAG oil helps in the management of body weight through weight loss’
Vlagatelj je predlagal naslednjo trditev: „Uživanje diacilglicerolnega olja namesto običajnega rastlinskega olja pomaga uravnavati telesno težo med hujšanjem.“
On 5 December 2011, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of DAG oil (as a replacement of triacylglycerol oils) and the claimed effect.
Komisija in države članice so 5. decembra 2011 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem diacilglicerolnega olja (kot nadomestka triacilglicerolnih olj) in navedeno trditvijo ni utemeljena.
Following an application from Giuliani S.p.A., submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006 and including a request for protection of proprietary data, the Authority was required to deliver an opinion on a health claim related to the effects of spermidine and prolongation of the growing phase (anagen) of the hair cycle (Question No EFSA-Q-2011-00896) [7].
Družba Giuliani S.p.A. je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, vključno z zahtevo za zaščito podatkov o lastništvu, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki spermidina na podaljšanje faze rasti (anagenske faze) v ciklusu rasti las (vprašanje št. EFSA-Q-2011-00896) [7].
The claim proposed by the applicant was worded as follows: ‘Spermidine prolongs the growing phase (anagen) of the hair cycle’.
Vlagatelj je predlagal naslednjo trditev: „Spermidin podaljšuje fazo rasti (anagensko fazo) v ciklusu rasti las.“
On 7 December 2011, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, the claimed effect is related to pathological conditions leading to the shortening of the anagen phase of hair growth and relates thus to the treatment of a disease.
Komisija in države članice so 7. decembra 2011 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da je navedena trditev povezana s patološkim stanjem, ki vodi do skrajšanja anagenske faze v ciklusu rasti las, s čimer je povezana tudi z zdravljenjem bolezni.
Regulation (EC) No 1924/2006 complements the general principles of Directive 2000/13/EC of the European Parliament and of the Council of 20 March 2000 on the approximation of the laws of the Member States relating to the labelling, presentation and advertising of foodstuffs [8].
Uredba (ES) št. 1924/2006 dopolnjuje splošna načela Direktive 2000/13/ES Evropskega parlamenta in Sveta z dne 20. marca 2000 o približevanju zakonodaj držav članic v zvezi z označevanjem, predstavljanjem in oglaševanjem živil [8].
Article 2(1)(b) of Directive 2000/13/EC provides that the labelling shall not attribute to any foodstuff the property of preventing, treating or curing a human disease, or refer to such properties.
Kot to določa člen 2(1)(b) Direktive 2000/13/ES, označbe na živilih ne smejo trditi ali opozarjati, da lahko živilo prepreči, zdravi ali ozdravi bolezni pri ljudeh.
Accordingly, as the attribution of medicinal properties to foods is prohibited, the claim related to the effects of spermidine should not be authorised.
Ker je pripisovanje zdravilnih lastnosti živilom prepovedano, trditev o učinkih spermidina ne bi smela biti dovoljena.
Following an application from Clasado Ltd, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of galacto-oligosaccharides from Bimuno® (Bimuno® GOS) and reducing gastro-intestinal discomfort (Question No EFSA-Q-2011-00401) [9].
Družba Clasado Ltd je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki galakto-oligosaharidov Bimuno® (Bimuno® GOS) na zmanjšanje prebavnih motenj (vprašanje št. EFSA-Q-2011-00401) [9].
The claim proposed by the applicant was worded as follows: ‘Regular daily consumption of 1,37 g galacto-oligosaccharides from Bimuno® may reduce intestinal discomfort’.
Vlagatelj je predlagal naslednjo trditev: „Redno dnevno uživanje 1,37 g galakto-oligosaharidov Bimuno® lahko zmanjša prebavne motnje.“
On 8 December 2011, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of Bimuno® GOS and the claimed effect.
Komisija in države članice so 8. decembra 2011 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem Bimuno® GOS in navedeno trditvijo ni utemeljena.
Following an application from Nordic Sugar A/S., submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of sugar beet fibre and decreasing intestinal transit time (Question No EFSA-Q-2011-00971) [10].
Družba Nordic Sugar A/S je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki vlaknin sladkorne pese na skrajšanje časa prehajanja črevesne vsebine (vprašanje št. EFSA-Q-2011-00971) [10].
The claim proposed by the applicant was worded as follows: ‘Sugar beet fibre decreases intestinal transit time’.
Vlagatelj je predlagal naslednjo trditev: „Vlaknine sladkorne pese skrajšujejo čas prehajanja črevesne vsebine.“
On 8 December 2011, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of sugar beet fibre and the claimed effect.
Komisija in države članice so 8. decembra 2011 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem vlaknin sladkorne pese in navedeno trditvijo ni utemeljena.
The health claim related to the effects of spermidine and prolongation of the growing phase (anagen) of the hair cycle, is a health claim attributing medicinal properties to the food subject to the claim and is therefore prohibited for foods.
Zdravstvena trditev o učinkih spermidina na podaljšanje faze rasti (anagenske faze) v ciklusu rasti las pripisuje zdravilne učinke živilu, na katerega se trditev nanaša, in je prepovedana za živila.
The health claims related to ‘hypo-caloric snacks (KOT products)’ and to diacylglycerol (DAG) oil are health claims as those referred to in point (c) of Article 13(1) of Regulation (EC) No 1924/2006 which are subject to the transitional period laid down in Article 28(6) of that Regulation.
Zdravstveni trditvi o „hipokaloričnih prigrizkih (izdelkih KOT)“ in diacilglicerolnem olju sta zdravstveni trditvi, podobni tistim iz člena 13(1)(c) Uredbe (ES) št. 1924/2006, zato zanju velja prehodno obdobje iz člena 28(6) navedene uredbe.
However, as the applications were not made before 19 January 2008, the requirement provided for in point (b) of Article 28(6) of that Regulation is not fulfilled, and therefore those claims may not benefit from the transitional period provided for in that Article.
Ker vlogi nista bili predloženi pred 19. januarjem 2008, zahteva iz člena 28(6)(b) navedene uredbe ni izpolnjena, zato se prehodno obdobje iz navedenega člena za navedeni trditvi ne more uporabiti.
The other health claims subject to this Regulation are health claims as referred to in point (a) of Article 13(1) of Regulation (EC) No 1924/2006, which are subject to the transitional period laid down in Article 28(5) of that Regulation until the adoption of the list of permitted health claims provided that they comply with that Regulation.
Druge zdravstvene trditve iz te uredbe so zdravstvene trditve, kot jih navaja člen 13(1)(a) Uredbe (ES) št. 1924/2006, za katere velja prehodno obdobje, določeno v členu 28(5) navedene uredbe, do sprejetja seznama dovoljenih zdravstvenih trditev, pod pogojem, da so skladne z navedeno uredbo.